在本研究中，中風患者患側上肢在接受肉毒桿菌治療後，用 modified Ashworth scale 和 modified Tardieu scale 評估肌肉痙攣，有明 顯的療效改善，療效可維持 12 週，受試者沒有任何不適的副作用；
而對於協同反應的改善，受試者在接受肉毒桿菌治療後，其協同反應 也有顯著減少，療效至少可維持 6 週。
至於上肢肌肉痙攣和步行能力及步態的關係，我們發現在治療後 受試者的步長有顯著增加，步寬顯著減少，而步行速度也有逐漸增加 的趨勢。至於運動學的部分，則發現患側膝關節的外展，內收角度，
和肩關節的外展，內收，以及屈曲，伸直角度有顯著增加，此外健側 踝關節的內外翻角度也有增加，這些結果顯示在接受上肢的肌肉痙攣 治療後，中風患者的步態也有改善。
在將來的研究我們可以用更客觀量化的評估方法來評估協同反 應，此外針對步態分析的部分可以先將受試者的動作能力分類，而且 增加受試者人數，才不至於造成個別差異性太大。
參考資料
1.Sacco RL, Boden-Albala B, et al. Stroke incidence among white, black and Hispanic residents of an urban community. Am J Epidemiol 1998; 147: 259-268
2. Domboy ML, Basford JR, et al. Disability and use of rehabilitation services following stroke in Rochester, Minnesota. Stroke 1987; 18:
830-6
3. Hung T. Cerebrovascular disease in the Taiwan Area: past, present and future. J Formos Med Assoc 1993; 792: S103-111
4. Broderick JP, Kissela BM, et al. Excess burden of stroke among blacks varies by age and gender. Stroke 2002; 33: 351
5. Bohannon RW, Horton MG, et al. Importance of four variables of walking to patients with stroke. Int J Rehabil Res 1991; 14: 246-250 6. Wall JC, Turbull GI. Gait asymmetries in residual hemiplegia. Arch
Phys Med Rehab 1986; 67: 550-3
7. Von Schroeder HP, Coutts RD, et al. Gait parameters following stroke:
a practical assessment. J Rehabil Res Dev 1995; 32: 25-31
8. Brandstater MZ, Bruin H, et al. Hemiplegic gait: analysis of temporal variables. Arch Phys Med Rehabil 1983; 64: 585-7
9. Bohannon RW. Gait performance of hemiparetic stroke patients:
selected variable. Arch Phys Med Rehabil 1987; 68: 777-81
10. Hesse SA, Jahnke MT, et al. Gait outcome in ambulatory hemiparetic patients after a 4 week comprehensive rehabilitation program and prognostic factors. Stroke 1994; 25: 1999-2004
11. Nyberg L, Gustafson Y. Fall prediction index for patients in stroke rehabilitation. Stroke 1997; 28: 716-21
12. DeQuervain IA, Sionon SR, et al. Gait pattern in the early recovery period after stroke. J Bone and Joint Surg 1996; 78: 1506-14
13. Chen CL, Chen HC, et al. Gait Performance with Compensatory adaptations in stroke patients with different degrees of motor recovery. Am J phys Med Rehabil 2003; 82: 925-935
14. Goldie PA, Matyac TA, et al. Deficit and change in gait velocity during rehabilitation after stroke. Arch Phys Med Rehabil 1996; 7:
1074-1082
15. Wolf PA. Epidemiology of stroke. Stroke pathophysioloy diagnosis and management. Churchill Livingstone 2004, p13-30
16. Mulley G. Associated reactions in the hemiplegic arm. Scand J
17. Davies P. Steps to follow: a guide to the treatment of adult hemiplegia.
Berlin, 1985
18. Walshe FMR. On certain tonic and postural reflexes in hemiplegia with special reference to the so called ‘associated movements’. Brain 1923; 46: 2-37
19. Dvir Z, Penturin E, Prop I. The effect of graded effort on the severity of associated reactions in hemiplegic patients. Clin Rehabil 1996; 10:
155-158.
20. Lazarus J.C. Associated movement in hemiplegia: the effects of force exerted, limb usage and inhibitory training. Arch Phys Med Rehabil 1992; 73: 1044-49
21. AMO Bakheit, J Sawyer. The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait. Disabil Rehabil 2002, 24(10): 519-22
22. Little JW, Massagli TL, et al. Spasticity and associated abnormalities of muscle tone. In DeLisa JA ed. Rehabilitation medicine: principles and practice. Philadelphia: Linppincott, 1998: 997-1014
23. Cartlidge NE, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974, 23:
17-24
24. Garlaned DE, Menachem L, Keenam JA. Percutaneous phenol blocks to motor points of spastic forearm muscles in head-injuried adults.
Arch Phys Med Rehabil 1984; 65: 243-5
25. Keenan MAE, Eufocina ST, Stone L. Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity. J Hand Surg 1990; 15A: 340-6
26. Pearce LB, First ER, MacCallum RD. Pharmocologic characterization of botulinum toxin for basic science and medicine. Toxicon 1986;
35:1373-412
27. Gardner B, Jamous A, et al. Intrathecal baclofen- a multicenter clinical comparison of the Medtronics program. Paraplegia 1995; 33:
551-4
28. Park TS, Gaffney PE, et al. Selective lumbosacral dorsal rhyzotomy caudal to the conus medullaris for cerebral palsy spasticity.
Neurosurgery 1993; 33: 929-33
29. Aoki KR, Guyer B. Botulinum toxin type A and the botulinum toxin serotypes. Eur J Neurol 2001; 8 (supp 5: 21-9)
neuromuscular junction. J physiology 1985; 109: 10-24
31. Dolly Jo, Black J, Williams RS. Receptors for botulinum toxin reside on motor nerve terminals and mediate its internalization. Nature 1984; 307: 57-60
32. Preiss RA, Condie DN, Rowley DI. The effects of botulinum toxin on spasticity of the lower limb and on gait in cerebral palsy. J Bone Joint Surg 2003; 85: 943-8
33. Simpson DM, Alexander DN, et al. Botulinum toxin type A in the treatment of upper extremity spasticity. Neurology 1996; 46:
1306-10
34. Boyd RN Boyd, Graham HK. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin in children with cerebral palsy. Dev Med Child Neurol 2000; 42: 32-41
35. Corry IS, Cosgrone AP. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997; 39: 185-93 36. Boyd RN, Graham HK. Botulinum toxin A in the management of
children with cerebral palsy. Euro J Neurol 1997; 4: (suppl): 15-22 37. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin
type A in the management of children with cerebral palsy. Europ J
Neurol 2001; 8(suppl 5): 1-20
38. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206-7
39. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999; 6: S23-35
40. Macfarlane A, Tumer L. The associated reaction rating scale: a clinical tool to measure associated reactions in the hemiplegic upper limb. Clin Rehabil 2002; 16: 726-35
41. Smith S, Ellis E, et al. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury.
Clin Rehabil 2000; 14: 5-13
42. Brashear A, Zafonte R, et al. Inter and intra-rater reliability of the Ashworth scale and the disability assessment scale in patients with upper limb poststroke spasticity. Arch Phys Med Rehabil 2002; 53:
1349-54
43. Mehrholz J, Wagner K, et al. Reliability of the modified Tardieu scale and the modified Ashworth scale in adult patients with severe brain
44. Scholtes S, Becher J, et al. Clinical assessment of spasticity in children with cerebral palsy: a critical reviews of available instruments. Dev Med Child Neurol 2006; 48: 64-73
45. Gracies J, Marosszeky J, et al. Short –term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch phys Med Rehabil 2000; 81: 1547-55
46. Dickenstein R, Heffes Y, Abbulaffio N. Electromyographic and positional changes in the elbows of spastic hemiparetic patients during walking. Electro and Clin Neuro 1996; 101: 491-496
47. Dvir Z, Panturin E. Measurement of spasticity and associated reactions in stroke patient before and after physiotherapeutic intervension. Clin Rehabil 1993; 7: 15-21
48. Hirsch MA, Westhoff B, et al. Association between botulinum toxin injection into the arm and changes in gait in adults after stroke.
Movement Dis 2005; 20: 1014-20
49.Bosales RL, Arimura K, et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin A injection. Muscle Nerve 1996; 19:
488-96
50. Garner CG, Stranbe A, et al. Time course of distant effects of local
injection of botulinum toxin. Movement Dis 1993; 8: 33-7
51. Panri F, Bosfa L. Botulinum toxin A treatment on spastic paraparesis:
a neurophysiological study. J Neurol Sci 2000; 181: 89-97
52. Modugno N, Priori A, et al. Botulinum toxin restores presynaptic inhibition of group Ia afferents in patients with essential tremor.
Muscle Nerve 1998; 12: 1701-5
53. Byrnes MC, Thickbroom GW. The corticomotor representation of upper limb muscle in writer’s cramp and changes following botulinum toxin injection. Brain 1998; 121: 977-88